Blood clots and thrombosis with thrombocytopenia (TTS)
What public evidence exists on this topic, and what kind of evidence each piece is. Each section is a different kind of evidence from a different system; the numbers are never added together.
VAERS reports Adverse-event report (unverified)
- 221 COVID-19 vaccine reports listing cerebral venous sinus thrombosis rows
- 1,112 COVID-19 vaccine reports listing thrombocytopenia rows
- cerebral venous sinus thrombosis
- thrombocytopenia
VAERS reports are unverified, have no denominator, and do not show that a vaccine caused anything. One report can list several terms, so terms overlap.
V-safe structured check-ins Self-reported health event
V-safe's check-the-box questions recorded general categories (symptoms, missed work, medical care, hospitalization), not specific conditions, so they hold no blood clots and thrombosis with thrombocytopenia (tts)-specific counts. See Safety Data for the category counts.
V-safe narratives Self-reported health event
The narrative index is not available yet.
FDA and CDC findings and actions Regulatory signal / recognized adverse reaction
- Regulatory safety signal CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets Lifted
CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses. - Recognized adverse reaction FDA and CDC lift the Janssen pause and add a clotting warning Superseded
After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets. - Other public record CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine Superseded
ACIP recommended mRNA vaccines over the Janssen vaccine for adults, citing the risk of thrombosis with thrombocytopenia syndrome; CDC adopted the recommendation. - Recognized adverse reaction FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome Superseded
FDA limited authorized use of the Janssen vaccine to adults for whom other COVID-19 vaccines were not accessible or clinically appropriate, or who would otherwise not be vaccinated, after determining that the risk of thrombosis with thrombocytopenia syndrome (rare, potentially life-threatening clots with low platelets, with onset about one to two weeks after vaccination) warranted the restriction. - Other public record FDA revokes the Janssen vaccine's emergency authorization at the company's request Withdrawn
Janssen asked FDA to withdraw the authorization because the last U.S. government lots had expired, there was no demand, and it did not intend to update the vaccine; FDA revoked it.
Compensation (CICP) Compensation claim / claim compensated
- 830 CICP COVID-19 vaccine claims whose alleged injury text mentions this topic (as of Jul 1, 2026) rows
- No compensated COVID-19 vaccine claim in HRSA's Table 4 lists a covered injury matching this topic.
Claims are allegations; a payment is a program determination under CICP rules, not a scientific finding. COVID-19 vaccines are not covered by the VICP.
Litigation Lawsuit allegation
No tracked case is tagged with this topic.
Studies and public records Epidemiologic association / public record
No study or public record on this topic has been added yet.